The main purpose of CORE C is to provide a large number of human specimens from well-defined patient cohorts to the scientific projects and the Technology Development Core of the Collaborative Research Center. As before, a primary focus of the core will be to maintain a large tissue bank of liver tissue samples from patients with and without HCV infection. The core will also provide and collect histopathological assessment of disease stage and status in combination with clinical information Furthermore, the core will coordinate the ongoing collection of blood/tissue samples, including large numbers of PBMC via buffy coat and leukapheresis protocols, maintain databases of available research samples together with relevant clinical data and will coordinate distribution of tissue, PBMC and plasma/serum samples among the investigators. Specifically the core will: 1) Collect longitudinal specimens, including large numbers of PBMC from leukapheresis, subjects with chronic HCV infection undergoing DAA therapy. from 2) Maintain and expand a large repository of PBMC from subjects with chronic HCV infection, resolved HCV infection and healthy controls, including large numbers of PBMC from buffy coats and leukapheresis.DD 3) Maintain and expand a large tissue bank of HCV-infected and non-HCV control tissue consisting of liver explant samples, surgical resection specimens and liver biopsies and provide liver-infiltrating lymphocytes derived from fine-needle aspirate samples. DD 4) Maintain an established database of all research specimens and available patient information and coordinate all aspects of sample collection and distribution.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19AI082630-06
Application #
8726067
Study Section
Special Emphasis Panel (ZAI1-LAR-I (J1))
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
6
Fiscal Year
2014
Total Cost
$226,634
Indirect Cost
$63,095
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Rowe, Ian A; Tully, Damien C; Armstrong, Matthew J et al. (2016) Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl 22:287-97
Fergusson, J R; Hühn, M H; Swadling, L et al. (2016) CD161(int)CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut. Mucosal Immunol 9:401-13
Attanasio, John; Wherry, E John (2016) Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity 44:1052-68
Llibre, Alba; López-Macías, Constantino; Marafioti, Teresa et al. (2016) LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 Downregulation. J Immunol 196:2085-94
Kurioka, Ayako; Walker, Lucy J; Klenerman, Paul et al. (2016) MAIT cells: new guardians of the liver. Clin Transl Immunology 5:e98
van Wilgenburg, Bonnie; Scherwitzl, Iris; Hutchinson, Edward C et al. (2016) MAIT cells are activated during human viral infections. Nat Commun 7:11653
Jeffery, Hannah C; van Wilgenburg, Bonnie; Kurioka, Ayako et al. (2016) Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1. J Hepatol 64:1118-27
Kelly, Christabel; Swadling, Leo; Capone, Stefania et al. (2016) Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. Hepatology 63:1455-70
Chusri, Pattranuch; Kumthip, Kattareeya; Hong, Jian et al. (2016) HCV induces transforming growth factor β1 through activation of endoplasmic reticulum stress and the unfolded protein response. Sci Rep 6:22487
Swadling, Leo; Halliday, John; Kelly, Christabel et al. (2016) Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. Vaccines (Basel) 4:

Showing the most recent 10 out of 128 publications